Letizia Dondi, Giulia Ronconi, Leonardo Dondi, Irene Dell'Anno, Silvia Calabria, Alice Addesi, Immacolata Esposito, Aldo P Maggioni, Nello Martini, Carlo Piccinni
{"title":"Il ruolo della Real World Evidence nella fase pre-marketing dei farmaci: le esperienze e le prospettive future di Fondazione ReS nel delineare i confini delle Target Population.","authors":"Letizia Dondi, Giulia Ronconi, Leonardo Dondi, Irene Dell'Anno, Silvia Calabria, Alice Addesi, Immacolata Esposito, Aldo P Maggioni, Nello Martini, Carlo Piccinni","doi":"10.1701/4392.43928","DOIUrl":null,"url":null,"abstract":"<p><p>The role of Real-World Evidence (RWE) concerns the entire drug lifecycle; despite widely recognised in the post-marketing, it is still debated in the pre-marketing, mainly as per the identification and analysis of target populations (TPs) for new drugs or indications. Through administrative healthcare databases, Research and Health Foundation (ReS), in collaboration with experts, develops algorithms to select and analyse TPs. As of March 2024, 85 TPs in 15 clinical areas have been analysed, of which oncology is the most represented. Findings on prevalence and incidence of specific diseases (or subpopulations), patient characteristics and costs directly charged to the Italian National Health Service, are provided. These are useful for healthcare institutions and pharmaceutical companies. In the future, efforts will focus on the development of tools based on artificial intelligence and synthetic data to improve analyses of TPs and support regulatory decisions on drugs.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 12","pages":"620-621"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recenti progressi in medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1701/4392.43928","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
真实世界证据(RWE)的作用涉及药物的整个生命周期;尽管在上市后得到广泛认可,但在上市前仍存在争议,主要是在新药或适应症目标人群(TPs)的识别和分析方面。研究与健康基金会(Research and Health Foundation,简称 ReS)与专家合作,通过行政医疗保健数据库,开发了选择和分析目标人群的算法。截至 2024 年 3 月,已对 15 个临床领域的 85 个 TPs 进行了分析,其中肿瘤学领域的分析最多。分析结果涉及特定疾病(或亚人群)的流行率和发病率、患者特征以及直接向意大利国家医疗服务机构收取的费用。这些信息对医疗机构和制药公司很有帮助。未来的工作重点将是开发基于人工智能和合成数据的工具,以改进对治疗方案的分析,并为药品监管决策提供支持。
Il ruolo della Real World Evidence nella fase pre-marketing dei farmaci: le esperienze e le prospettive future di Fondazione ReS nel delineare i confini delle Target Population.
The role of Real-World Evidence (RWE) concerns the entire drug lifecycle; despite widely recognised in the post-marketing, it is still debated in the pre-marketing, mainly as per the identification and analysis of target populations (TPs) for new drugs or indications. Through administrative healthcare databases, Research and Health Foundation (ReS), in collaboration with experts, develops algorithms to select and analyse TPs. As of March 2024, 85 TPs in 15 clinical areas have been analysed, of which oncology is the most represented. Findings on prevalence and incidence of specific diseases (or subpopulations), patient characteristics and costs directly charged to the Italian National Health Service, are provided. These are useful for healthcare institutions and pharmaceutical companies. In the future, efforts will focus on the development of tools based on artificial intelligence and synthetic data to improve analyses of TPs and support regulatory decisions on drugs.
期刊介绍:
Giunta ormai al sessantesimo anno, Recenti Progressi in Medicina continua a costituire un sicuro punto di riferimento ed uno strumento di lavoro fondamentale per l"ampliamento dell"orizzonte culturale del medico italiano. Recenti Progressi in Medicina è una rivista di medicina interna. Ciò significa il recupero di un"ottica globale e integrata, idonea ad evitare sia i particolarismi della informazione specialistica sia la frammentazione di quella generalista.